<DOC>
	<DOCNO>NCT00602836</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , pentostatin cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Lenalidomide may stop growth cancer cell block enzymes need cell growth . Giving rituximab together combination chemotherapy lenalidomide may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together pentostatin , cyclophosphamide , lenalidomide work treat patient previously untreated B-cell chronic lymphocytic leukemia small lymphocytic lymphoma .</brief_summary>
	<brief_title>Rituximab , Pentostatin , Cyclophosphamide , Lenalidomide Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess rate complete overall response use pentostatin , cyclophosphamide , rituximab ( PCR ) follow consolidation lenalidomide patient previously untreated B-cell chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma . Secondary - To assess proportion patient convert nodular partial response ( nPR ) , PR , stable disease complete PCR complete response ( CR ) 6 cycle consolidation lenalidomide . - To assess proportion patient convert CR detectable minimal residual disease ( MRD ) PCR CR MRD negative state 6 course consolidation lenalidomide . - To assess proportion patient convert CR detectable MRD , nPR , PR , stable disease residual disease PCR CR MRD negative state 6 cycle consolidation lenalidomide . - To monitor assess toxicity regimen . - To determine molecular prognostic parameter ( e.g. , ZAP-70 , CD38 , cytogenetic abnormality identify FISH , IgVH mutation status ) relate response PCR-lenalidomide therapy . - To use evaluation MRD determine duration lenalidomide therapy . - To determine progression-free survival CLL patient use treatment regimen . OUTLINE : This multicenter study . - Induction therapy : Patients receive rituximab IV 4 hour day 1 2 course 1 , 1 hour day 1 subsequent course . Patients also receive pentostatin IV 30 minute cyclophosphamide IV 30 minute day 1 , pegfilgrastim subcutaneously day 2 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Consolidation therapy : Beginning 2 month completion induction therapy , patient receive oral lenalidomide daily day 1-28 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Continuation therapy : Patients residual disease continue receive lenalidomide consolidation therapy achieve minimal residual disease-negative status complete remission . Patients achieve complete response detectable disease discontinue therapy enter observation phase . Blood sample collect periodically treatment translational pharmacologic study . Samples analyze immunoglobulin heavy chain gene mutational status , ZAP-70 status , level VEGF , bFGF , thrombospondin , TGF-beta ELISA ; effect therapy immune function . Samples also store future research . Bone marrow aspirate sample analyze minimal residual disease flow cytometry . After completion study treatment , patient follow every 90 day 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) , meet follow criterion : Biopsyproven SLL accord WHO criteria CLL diagnosis* accord NCI work group criterion evidence follow : Peripheral blood lymphocyte count &gt; 5,000/mm³ Small moderate peripheral blood lymphocyte &lt; 55 % prolymphocytes Immunophenotyping consistent CLL define : Bcell marker CD5 antigen absence panTcell marker ( e.g. , CD3 , CD2 ) CD19 , CD20 , CD23 Dim surface immunoglobulin expression Exclusively kappa lambda light chain Diagnosis mantle cell lymphoma must exclude negative FISH analysis ( 11 ; 14 ) ( IgH/CCND1 ) peripheral blood tissue biopsy negative immunohistochemical stain cyclin D1 involved tissue biopsy NOTE : *Splenomegaly , hepatomegaly , lymphadenopathy require diagnosis CLL Previously untreated disease meet ≥ 1 follow criteria* : At least 1 follow diseaserelated symptom : Weight loss &gt; 10 % within previous 6 month Extreme fatigue attribute CLL Fevers &gt; 100.5º F 2 week without evidence infection Night sweat without evidence infection Evidence progressive marrow failure manifest development worsen anemia ( i.e. , hemoglobin ≤ 11 g/dL ) and/or thrombocytopenia ( i.e. , platelet count ≤ 100,000/mm³ ) due autoimmune disease Symptomatic progressive lymphadenopathy , splenomegaly , hepatomegaly Progressive lymphocytosis due CLL increase &gt; 50 % 2month period anticipate doubling time &lt; 6 month NOTE : *Marked hypogammaglobulinemia development monoclonal protein absence criterion active disease sufficient protocol therapy PATIENT CHARACTERISTICS : ECOG performance status 03 Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 3.0 time ULN ( unless due Gilbert disease ) Direct bilirubin &lt; 1.5 mg/dL Gilbert disease diagnose total bilirubin &gt; 3.0 time ULN AST ALT ≤ 3.0 time ULN ( unless due hemolysis CLL ) Willing provide blood sample Able take acetylsalicylic acid ( ASA ) ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use low molecular weight heparin ) Not pregnant nursing Negative pregnancy test Female patient must use effective doublemethod contraception begin 1 month prior , , 4 week completion study treatment Male patient must use effective contraception 4 week completion study treatment No comorbid condition , include follow : New York Heart Association class III IV heart disease Recent myocardial infarction ( &lt; 1 month ) Uncontrolled infection Infection HIV/AIDS No active primary malignancy require treatment limit survival ≤ 2 year No history deep venous thrombosis pulmonary embolism ≤ 12 month prior study registration No active hemolytic anemia require immunosuppressive pharmacologic therapy PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy monoclonal antibodybased therapy treatment CLL Nutraceutical treatment establish benefit CLL ( e.g. , epigallocatechin gallate herbal treatment ) consider prior therapy More 4 week since prior radiotherapy At least 4 week since prior major surgery No concurrent corticosteroid Concurrent low dos steroid ( e.g. , &lt; 10 mg prednisone equivalent dose steroid ) use treatment nonhematologic medical condition allow Prior use corticosteroid allow No prior thalidomide lenalidomide No concurrent therapeutic dos coumadinderivative anticoagulant ( e.g. , warfarin ) Doses ≤ 2 mg daily allow thrombosis prophylaxis Prophylactic dose low molecular weight heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>